Association of atrial fibrillation with all-cause mortality, cardiovascular mortality, and cancer-specific mortality at 1 year after cancer diagnosis: results from Cox proportional hazards model
| AF group and adjustment model . | HR (95% CI) . | ||
|---|---|---|---|
| All-cause mortality . | Cardiovascular mortality . | Cancer-specific mortality . | |
| Breast cancer patients with new-onset AF in first 30 days after breast cancer diagnosis (Group 1) | |||
| Model 1—unadjusted | 7.63 (6.50–8.96) | 8.99 (6.25–12.94) | 7.65 (6.20–9.43) |
| Model 2 | 7.68 (6.55–9.01) | 8.95 (6.22–12.89) | 7.71 (6.25–9.52) |
| Model 3 | 3.52 (2.34–5.28) | 6.43 (3.17–13.01) | 2.86 (1.57–5.22) |
| Model 4 | 3.94 (2.30–6.76) | 9.16 (3.71–22.63) | 2.44 (1.07–5.58) |
| Model 5 | 3.11 (2.06–4.68) | 5.46 (2.69–11.10) | 2.65 (1.44–4.87) |
| Model 6 | 2.20 (1.46–3.31) | 3.85 (1.89–7.84) | 1.85 (1.00–3.40) |
| Model 7 | 2.15 (1.32–3.48) | 3.00 (1.28–7.00) | 1.42 (0.77–2.62) |
| Breast cancer patients with AF prior to breast cancer diagnosis (Group 2) | |||
| Model 1—unadjusted | 2.26 (2.12–2.40) | 4.74 (4.17–5.40) | 1.63 (1.49–1.79) |
| Model 2 | 2.23 (2.10–2.38) | 4.76 (4.17–5.43) | 1.61 (1.47–1.76) |
| Model 3 | 2.28 (2.00–2.60) | 3.62 (2.85–4.60) | 1.58 (1.27–1.97) |
| Model 4 | 2.20 (1.82–2.66) | 3.72 (2.63–5.26) | 1.39 (1.01–1.92) |
| Model 5 | 1.54 (1.34–1.78) | 1.90 (1.46–2.48) | 1.29 (1.02–1.65) |
| Model 6 | 1.02 (0.88–1.18) | 1.27 (0.97–1.67) | 0.83 (0.65–1.06) |
| Model 7 | 0.91 (0.78–1.07) | 1.36 (1.00–1.84) | 0.75 (0.35–1.23) |
| AF group and adjustment model . | HR (95% CI) . | ||
|---|---|---|---|
| All-cause mortality . | Cardiovascular mortality . | Cancer-specific mortality . | |
| Breast cancer patients with new-onset AF in first 30 days after breast cancer diagnosis (Group 1) | |||
| Model 1—unadjusted | 7.63 (6.50–8.96) | 8.99 (6.25–12.94) | 7.65 (6.20–9.43) |
| Model 2 | 7.68 (6.55–9.01) | 8.95 (6.22–12.89) | 7.71 (6.25–9.52) |
| Model 3 | 3.52 (2.34–5.28) | 6.43 (3.17–13.01) | 2.86 (1.57–5.22) |
| Model 4 | 3.94 (2.30–6.76) | 9.16 (3.71–22.63) | 2.44 (1.07–5.58) |
| Model 5 | 3.11 (2.06–4.68) | 5.46 (2.69–11.10) | 2.65 (1.44–4.87) |
| Model 6 | 2.20 (1.46–3.31) | 3.85 (1.89–7.84) | 1.85 (1.00–3.40) |
| Model 7 | 2.15 (1.32–3.48) | 3.00 (1.28–7.00) | 1.42 (0.77–2.62) |
| Breast cancer patients with AF prior to breast cancer diagnosis (Group 2) | |||
| Model 1—unadjusted | 2.26 (2.12–2.40) | 4.74 (4.17–5.40) | 1.63 (1.49–1.79) |
| Model 2 | 2.23 (2.10–2.38) | 4.76 (4.17–5.43) | 1.61 (1.47–1.76) |
| Model 3 | 2.28 (2.00–2.60) | 3.62 (2.85–4.60) | 1.58 (1.27–1.97) |
| Model 4 | 2.20 (1.82–2.66) | 3.72 (2.63–5.26) | 1.39 (1.01–1.92) |
| Model 5 | 1.54 (1.34–1.78) | 1.90 (1.46–2.48) | 1.29 (1.02–1.65) |
| Model 6 | 1.02 (0.88–1.18) | 1.27 (0.97–1.67) | 0.83 (0.65–1.06) |
| Model 7 | 0.91 (0.78–1.07) | 1.36 (1.00–1.84) | 0.75 (0.35–1.23) |
Model 2: Model 1 + demographic features; Model 3: Model 2 + breast cancer-related features; Model 4: Model 3 + breast cancer tumour receptor subtype; Model 5: Model 3 + cardiovascular risk factors for AF; Model 6: Model 5 + breast cancer medication; Model 7: Model 6 + cardiac medications (beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, spironolactone/eplerenone). Detailed model description is presented in Supplementary material online, Table S2.
AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio.
Association of atrial fibrillation with all-cause mortality, cardiovascular mortality, and cancer-specific mortality at 1 year after cancer diagnosis: results from Cox proportional hazards model
| AF group and adjustment model . | HR (95% CI) . | ||
|---|---|---|---|
| All-cause mortality . | Cardiovascular mortality . | Cancer-specific mortality . | |
| Breast cancer patients with new-onset AF in first 30 days after breast cancer diagnosis (Group 1) | |||
| Model 1—unadjusted | 7.63 (6.50–8.96) | 8.99 (6.25–12.94) | 7.65 (6.20–9.43) |
| Model 2 | 7.68 (6.55–9.01) | 8.95 (6.22–12.89) | 7.71 (6.25–9.52) |
| Model 3 | 3.52 (2.34–5.28) | 6.43 (3.17–13.01) | 2.86 (1.57–5.22) |
| Model 4 | 3.94 (2.30–6.76) | 9.16 (3.71–22.63) | 2.44 (1.07–5.58) |
| Model 5 | 3.11 (2.06–4.68) | 5.46 (2.69–11.10) | 2.65 (1.44–4.87) |
| Model 6 | 2.20 (1.46–3.31) | 3.85 (1.89–7.84) | 1.85 (1.00–3.40) |
| Model 7 | 2.15 (1.32–3.48) | 3.00 (1.28–7.00) | 1.42 (0.77–2.62) |
| Breast cancer patients with AF prior to breast cancer diagnosis (Group 2) | |||
| Model 1—unadjusted | 2.26 (2.12–2.40) | 4.74 (4.17–5.40) | 1.63 (1.49–1.79) |
| Model 2 | 2.23 (2.10–2.38) | 4.76 (4.17–5.43) | 1.61 (1.47–1.76) |
| Model 3 | 2.28 (2.00–2.60) | 3.62 (2.85–4.60) | 1.58 (1.27–1.97) |
| Model 4 | 2.20 (1.82–2.66) | 3.72 (2.63–5.26) | 1.39 (1.01–1.92) |
| Model 5 | 1.54 (1.34–1.78) | 1.90 (1.46–2.48) | 1.29 (1.02–1.65) |
| Model 6 | 1.02 (0.88–1.18) | 1.27 (0.97–1.67) | 0.83 (0.65–1.06) |
| Model 7 | 0.91 (0.78–1.07) | 1.36 (1.00–1.84) | 0.75 (0.35–1.23) |
| AF group and adjustment model . | HR (95% CI) . | ||
|---|---|---|---|
| All-cause mortality . | Cardiovascular mortality . | Cancer-specific mortality . | |
| Breast cancer patients with new-onset AF in first 30 days after breast cancer diagnosis (Group 1) | |||
| Model 1—unadjusted | 7.63 (6.50–8.96) | 8.99 (6.25–12.94) | 7.65 (6.20–9.43) |
| Model 2 | 7.68 (6.55–9.01) | 8.95 (6.22–12.89) | 7.71 (6.25–9.52) |
| Model 3 | 3.52 (2.34–5.28) | 6.43 (3.17–13.01) | 2.86 (1.57–5.22) |
| Model 4 | 3.94 (2.30–6.76) | 9.16 (3.71–22.63) | 2.44 (1.07–5.58) |
| Model 5 | 3.11 (2.06–4.68) | 5.46 (2.69–11.10) | 2.65 (1.44–4.87) |
| Model 6 | 2.20 (1.46–3.31) | 3.85 (1.89–7.84) | 1.85 (1.00–3.40) |
| Model 7 | 2.15 (1.32–3.48) | 3.00 (1.28–7.00) | 1.42 (0.77–2.62) |
| Breast cancer patients with AF prior to breast cancer diagnosis (Group 2) | |||
| Model 1—unadjusted | 2.26 (2.12–2.40) | 4.74 (4.17–5.40) | 1.63 (1.49–1.79) |
| Model 2 | 2.23 (2.10–2.38) | 4.76 (4.17–5.43) | 1.61 (1.47–1.76) |
| Model 3 | 2.28 (2.00–2.60) | 3.62 (2.85–4.60) | 1.58 (1.27–1.97) |
| Model 4 | 2.20 (1.82–2.66) | 3.72 (2.63–5.26) | 1.39 (1.01–1.92) |
| Model 5 | 1.54 (1.34–1.78) | 1.90 (1.46–2.48) | 1.29 (1.02–1.65) |
| Model 6 | 1.02 (0.88–1.18) | 1.27 (0.97–1.67) | 0.83 (0.65–1.06) |
| Model 7 | 0.91 (0.78–1.07) | 1.36 (1.00–1.84) | 0.75 (0.35–1.23) |
Model 2: Model 1 + demographic features; Model 3: Model 2 + breast cancer-related features; Model 4: Model 3 + breast cancer tumour receptor subtype; Model 5: Model 3 + cardiovascular risk factors for AF; Model 6: Model 5 + breast cancer medication; Model 7: Model 6 + cardiac medications (beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, spironolactone/eplerenone). Detailed model description is presented in Supplementary material online, Table S2.
AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
